- Datum05.06.2025
- Uhrzeit08:55 - 18:30 Uhr
- Veranstalter
stock3
stock3
Moderator
Novartis AG Aktie
Verkaufen
Kaufen
Novartis AG Chart
Novartis AG Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (SIX)
1,40 %
Intraday
0,23 %
1 Woche
-0,19 %
1 Monat
6,01 %
Seit Jahresbeginn
0,92 %
1 Jahr
9,85 %
3 Jahre
13,85 %
5 Jahre
10,45 %
10 Jahre
Passender Service zu Novartis AG
Webinar zu Novartis AG
Kursinformationen (SIX)
- Tagestief / Hoch (Fr)-
- 52W-Tief / Hoch (Fr)81,100-102,720
- Jahrestief / Hoch (Fr)81,100-101,840
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Novartis AG
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2028 (e) | ||
| - | 2027 (e) | ||
| - | 2026 (e) | ||
| - | 2025 (e) | ||
| 11.03.2025 | 2024 | 3,50 Fr | 3,45 % |
| 07.03.2024 | 2023 | 3,30 Fr | 3,62 % |
| 09.03.2023 | 2022 | 3,20 Fr | 4,07 % |
| 08.03.2022 | 2021 | 3,10 Fr | 4,03 % |
| 04.03.2021 | 2020 | 3,00 Fr | 3,71 % |
| 03.03.2020 | 2019 | 2,95 Fr | 3,60 % |
| 04.03.2019 | 2018 | 2,85 Fr | 3,54 % |
| 06.03.2018 | 2017 | 2,80 Fr | 4,02 % |
| 02.03.2017 | 2016 | 2,75 Fr | 3,95 % |
| 25.02.2016 | 2015 | 2,70 Fr | 4,23 % |
| 03.03.2015 | 2014 | 2,60 Fr | 3,00 % |
| 27.02.2014 | 2013 | 2,45 Fr | 3,68 % |
| 26.02.2013 | 2012 | 2,30 Fr | 4,00 % |
| 27.02.2012 | 2011 | 2,25 Fr | 4,94 % |
| 24.02.2011 | 2010 | 2,20 Fr | 4,63 % |
| 02.03.2010 | 2009 | 2,10 Fr | 3,94 % |
| 27.02.2009 | 2008 | 2,00 Fr | 4,96 % |
| 29.02.2008 | 2007 | 1,60 Fr | 3,32 % |
| 09.03.2007 | 2006 | 1,35 Fr | 2,16 % |
| 03.03.2006 | 2005 | 1,15 Fr | 1,82 % |
| 04.03.2005 | 2004 | 1,05 Fr | 2,03 % |
| 27.02.2004 | 2003 | 1,00 Fr | 2,00 % |
| 07.03.2003 | 2002 | 0,95 Fr | 2,22 % |
| 26.03.2002 | 2001 | 0,90 Fr | 1,53 % |
| 27.03.2001 | 2000 | 34,00 Fr | - |
| 17.04.2000 | 1999 | 32,00 Fr | - |
| 26.04.1999 | 1998 | 29,00 Fr | - |
| 24.04.1998 | 1997 | 25,00 Fr | - |
| 25.04.1997 | 1996 | 20,00 Fr | - |
Termine von Novartis AG
- Jul17Novartis AGQ2 2025 Earnings Release
- Okt28Novartis AGQ3 2025 Earnings Release
- Feb4Novartis AGQ4 2025 Earnings Release
Beschreibung
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
